132 related articles for article (PubMed ID: 18503633)
21. Inhibition of cardiac hypertrophy by triflusal (4-trifluoromethyl derivative of salicylate) and its active metabolite.
Planavila A; Rodríguez-Calvo R; de Arriba AF; Sánchez RM; Laguna JC; Merlos M; Vazquez-Carrera M
Mol Pharmacol; 2006 Apr; 69(4):1174-81. PubMed ID: 16421291
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin.
Dudley A; Thomason J; Fritz S; Grady J; Stokes J; Wills R; Pinchuk L; Mackin A; Lunsford K
J Vet Intern Med; 2013; 27(1):141-9. PubMed ID: 23278865
[TBL] [Abstract][Full Text] [Related]
23. Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation.
Doutremepuich C; Aguejouf O; Desplat V; Eizayaga FX
Thromb Haemost; 2010 Jan; 103(1):171-80. PubMed ID: 20062937
[TBL] [Abstract][Full Text] [Related]
24. Triflusal.
McNeely W; Goa KL
Drugs; 1998 Jun; 55(6):823-33; discussion 834-5. PubMed ID: 9617597
[TBL] [Abstract][Full Text] [Related]
25. Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
Tailor A; Wood KC; Wallace JL; Specian RD; Granger DN
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3636-42. PubMed ID: 17933963
[TBL] [Abstract][Full Text] [Related]
26. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Alvarez-Sabín J; Quintana M; Santamarina E; Maisterra O
Cerebrovasc Dis; 2014; 37(3):181-7. PubMed ID: 24503927
[TBL] [Abstract][Full Text] [Related]
27. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries.
Liu B; Luo W; Zhang Y; Li H; Zhu N; Huang D; Zhou Y
Exp Physiol; 2012 Feb; 97(2):277-89. PubMed ID: 22080487
[TBL] [Abstract][Full Text] [Related]
28. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
29. Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.
Kaber G; Kaiser B; Baumgärtel-Allekotte D; Rauch B; Nossmann S; Heim Kh; Weber A; Nagy N; Fischer J; Schrör K
Br J Pharmacol; 2011 Sep; 164(2b):561-9. PubMed ID: 21457221
[TBL] [Abstract][Full Text] [Related]
30. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets.
García-Rafanell J; Ramis J; Gomez L; Forn J
Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):155-65. PubMed ID: 3030206
[TBL] [Abstract][Full Text] [Related]
31. Effects of triflusal and aspirin in a rat model of cerebral ischemia.
Whitehead SN; Bayona NA; Cheng G; Allen GV; Hachinski VC; Cechetto DF
Stroke; 2007 Feb; 38(2):381-7. PubMed ID: 17194886
[TBL] [Abstract][Full Text] [Related]
32. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection.
Torsney E; Mayr U; Zou Y; Thompson WD; Hu Y; Xu Q
Circ Res; 2004 Jun; 94(11):1466-73. PubMed ID: 15117816
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
Wang M; Zhang Q; Huang M; Zong S; Hua W; Zhou W
Drug Res (Stuttg); 2014 May; 64(5):263-8. PubMed ID: 24105106
[TBL] [Abstract][Full Text] [Related]
34. Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: influence of red blood cells and leukocytes.
de la Cruz JP; Pavia J; Bellido I; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1988 Jun; 10(6):363-7. PubMed ID: 3412046
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
Kim SW; Choi KJ; Park JY; Yoon SH; Lee JK
Neurosci Lett; 2017 Mar; 643():59-64. PubMed ID: 28189746
[TBL] [Abstract][Full Text] [Related]
36. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
[TBL] [Abstract][Full Text] [Related]
37. Triflusal for preventing serious vascular events in people at high risk.
Costa J; Ferro JM; Matias-Guiu J; Alvarez-Sabin J; Torres F
Cochrane Database Syst Rev; 2005 Jul; (3):CD004296. PubMed ID: 16034926
[TBL] [Abstract][Full Text] [Related]
38. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Tuleja E; Mejza F; Cmiel A; Szczeklik A
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
[TBL] [Abstract][Full Text] [Related]
39. Platelet adhesivity to subendothelium is influenced by polymorphonuclear leukocytes: studies with aspirin and salicylate.
Hernández R; Alemany M; Bozzo J; Buchanan MR; Ordinas A; Bastida E
Haemostasis; 1993; 23(1):1-7. PubMed ID: 8477903
[TBL] [Abstract][Full Text] [Related]
40. Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway.
Blanco-Rivero J; Márquez-Rodas I; Xavier FE; Aras-López R; Arroyo-Villa I; Ferrer M; Balfagón G
Cardiovasc Res; 2007 Jul; 75(2):398-407. PubMed ID: 17412316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
